Physician profile
Warren T Yamashita
NPI 1982137691
$1,373.55
in general payments reported to CMS, 2019-2025
20 companies · $807 in 2025
The $807 reported for 2025 was more than what 87% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.98 · 2021: $58.54 · 2023: $24.45 · 2024: $465 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $287.46 | 2024-2025 | |
| Viiv Healthcare Company | $167.11 | 2024-2025 | Apretude |
| Indivior INC. | $151.75 | 2021-2025 | Sublocade |
| Gilead Sciences, INC. | $87.44 | 2025 | |
| Braeburn INC. | $82.04 | 2024-2025 | Brixadi |
| Amgen INC. | $77.05 | 2024-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $69.98 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $67.76 | 2024-2025 | Zepbound, Mounjaro |
| Sage Therapeutics, LLC | $55.62 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $53.59 | 2024-2025 | |
| Madrigal Pharmaceuticals | $40.24 | 2025 | Rezdiffra |
| Pfizer INC. | $38.28 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $31.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.69 | 2025 | Caplyta |
| Dexcom, INC. | $28.14 | 2024 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $25.47 | 2025 | Qelbree |
| Astellas Pharma US INC | $23.61 | 2024 | Veozah |
| Abbott Laboratories | $21.46 | 2024 | Piccolo Xpress |
| Reprise Biomedical, INC. | $19.09 | 2024 | Miro3d |
| Exact Sciences Corporation | $17.77 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Yamashita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.